company background image
74C logo

Crossject Société Anonyme DB:74C Stock Report

Last Price

€1.87

Market Cap

€88.2m

7D

-1.5%

1Y

-56.0%

Updated

26 Nov, 2024

Data

Company Financials +

Crossject Société Anonyme

DB:74C Stock Report

Market Cap: €88.2m

Crossject Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Crossject Société Anonyme
Historical stock prices
Current Share Price€1.87
52 Week High€5.76
52 Week Low€1.43
Beta0.85
11 Month Change-20.68%
3 Month Change-12.93%
1 Year Change-56.00%
33 Year Change-28.28%
5 Year Change-17.17%
Change since IPO-83.27%

Recent News & Updates

Recent updates

Shareholder Returns

74CDE Medical EquipmentDE Market
7D-1.5%2.9%0.8%
1Y-56.0%-4.7%8.6%

Return vs Industry: 74C underperformed the German Medical Equipment industry which returned -5% over the past year.

Return vs Market: 74C underperformed the German Market which returned 9.1% over the past year.

Price Volatility

Is 74C's price volatile compared to industry and market?
74C volatility
74C Average Weekly Movement9.1%
Medical Equipment Industry Average Movement5.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 74C's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 74C's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2001112Patrick Alexandrewww.crossject.com

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.

Crossject Société Anonyme Fundamentals Summary

How do Crossject Société Anonyme's earnings and revenue compare to its market cap?
74C fundamental statistics
Market cap€88.19m
Earnings (TTM)-€10.48m
Revenue (TTM)€2.36m

37.4x

P/S Ratio

-8.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
74C income statement (TTM)
Revenue€2.36m
Cost of Revenue€10.26m
Gross Profit-€7.91m
Other Expenses€2.57m
Earnings-€10.48m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin-335.65%
Net Profit Margin-444.74%
Debt/Equity Ratio-583.0%

How did 74C perform over the long term?

See historical performance and comparison